查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970821

靜脈血栓栓塞症預防市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、最終用途、地區和競爭格局分類，2021-2031年

Venous Thromboembolism Prophylaxis Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By End Use, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球靜脈血栓栓塞症預防市場預計將從 2025 年的 68.9 億美元成長到 2031 年的 95.7 億美元，複合年成長率為 5.63%。

此治療領域涉及抗凝血劑的使用和機械加壓裝置的應用，旨在預防深層靜脈栓塞症和肺動脈栓塞。市場成長趨勢的主要促進因素是全球人口老化以及需要嚴格術後預防保健的大型心臟和整形外科手術住院率的不斷上升。此外，人們日益認知到醫院獲得性血栓症形成是一種可預防的死亡原因，這也持續推動了醫療機構對有效干預通訊協定的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 68.9億美元
市場規模：2031年 95.7億美元
複合年成長率：2026-2031年 5.63%
成長最快的細分市場 門診部
最大的市場 北美洲

儘管有這些成長要素，強效藥物相關的出血風險仍然是一個主要障礙，可能導致臨床醫生無法嚴格遵守預防指引。這種謹慎的做法限制了市場滲透率，儘管需要關注的凝血障礙盛行率很高。根據國際血栓與止血學會的數據，到2024年，血栓症相關疾病將佔全球死亡人數的四分之一，凸顯了在擴大預防措施覆蓋範圍時，平衡治療效果與患者安全至關重要。

市場促進因素

大型外科手術和整形外科手術數量的增加是推動市場成長的關鍵因素，因此需要嚴格的術後預防策略以確保病人安全。隨著醫療系統逐步清除與疫情相關的未治療病例，全膝關節和髖置換術等高風險手術的頻率也在增加，這直接推動了藥物預防和機械置換術的使用。隨著手術量的增加，儲備和使用預防性解決方案以降低與手術傷口和長期煞車相關的深層靜脈栓塞症形成風險，已成為醫院的必要之舉。根據史賽克公司於2024年1月發布的2023年第四季財報，該公司淨銷售額成長11.5%，達到58億美元。這一業績主要歸功於需要同時進行預防性護理的手術數量的持續成長。

同時，新型口服抗凝血劑（NOACs）的快速普及正在改變標準治療方案，與傳統維生素K拮抗劑相比，NOACs具有更優的安全性和更便捷的給藥方式。臨床醫生越來越傾向於選擇這些先進的療法，因為其可預測的藥物動力學特性能夠提高患者的依從性，並減少持續監測的需求。根據百時美施貴寶公司2023會計年度（2024年2月）的年度報告，其旗艦口服抗凝血劑艾樂妥（Eliquis）的全球銷售額達到122億美元，顯示全球正在發生向這些現代藥物的大規模轉變。持續的疾病負擔進一步凸顯了這一轉變。根據美國血栓症）預測，到2024年，美國每年將有約90萬人受到血栓症的影響，這更加凸顯了在整個治療過程中採取可靠的預防干涉措施的迫切性。

市場挑戰

全球靜脈血栓栓塞症預防市場面臨的主要障礙之一是強效抗凝血​​治療相關的嚴重出血風險。臨床醫生經常面臨兩難：既要權衡血栓預防的益處，又要考慮可能危及生命的出血併發症，尤其是在老年人和術後康復患者等脆弱人群中。這種臨床謹慎往往導致處方不足、劑量減重或過早停止必要的預防性治療。雖然這些顧慮在臨床上是合理的，但它們限制了抗凝血劑的整體使用，並延緩了預防通訊協定的推廣，阻礙了市場的整體成長。

這種限制在高風險患者族群中尤為嚴重，而這類人群恰恰佔目標市場的很大一部分。根據美國血液學會統計，2023年，住院病患和長期照護機構的居民約佔全球所有靜脈血栓栓塞症病例的20%至25%。由於這些特定族群通常合併多種疾病，增加了出血風險，因此出於安全考慮，嚴格執行預防措施往往受到阻礙，從而有效地限制了市場滲透，而這部分人群原本會對預防性干預措施產生巨大的需求。

市場趨勢

攜帶式穿戴式機械預防設備的興起，正在改變復健方式，使壓迫療法擺脫對固定醫院環境的依賴。與將患者限制在床邊的傳統氣動系統不同，這些電池驅動裝置能夠讓患者儘早活動，這對於減少靜脈淤血和提高出院後患者的依從性至關重要。這種轉變順應了人們對居家復健解決方案日益成長的需求，這些方案既能保持臨床療效，又不限制患者的活動能力。主要產業參與者的財務表現凸顯了這些技術的商業性可行性。根據Enobis公司於2024年2月發布的“2023會計年度第四季度及全年業績報告”，該公司預防與康復部門的全年淨銷售額成長了5%，反映了市場對這些移動治療解決方案的持續需求。

同時，利用人工智慧驅動的風險評估進行個人化預防通訊協定的採用正日益普及，成為精準醫療工具，取代了傳統的通用預防策略。先進的演算法與電子健康記錄系統整合，持續監測患者數據，並自動識別可能被人工評分系統（例如帕多瓦評分和卡普利尼評分）遺漏的高風險患者。這種自動化確保了對肺動脈栓塞等疾病的及時干預，並改善了分散的醫院部門之間的護理協調。這些智慧型系統的快速普及也體現在專業人工智慧提供者日益成長的影響力上。根據 Viz.ai 於 2024 年 1 月發布的新聞稿《Viz.ai 在美國的醫院應用程式已超過 1500 家》，其人工智慧疾病檢測平台的用戶群在 2023 年成長了約 30%，達到 45,000 名醫療保健提供者。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：靜脈血栓栓塞症預防的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（下肢、上肢）
    • 依用途（醫院/診所、門診部、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美靜脈血栓栓塞症預防市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲靜脈血栓栓塞症預防市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區靜脈血栓栓塞症預防市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章 中東和非洲靜脈靜脈血栓栓塞症預防市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲靜脈血栓栓塞症預防市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球靜脈血栓栓塞症預防市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Arjo
  • Encompass Group
  • Argon Medical Devices
  • MEGO AFEK
  • Zenith Technical Innovations
  • Cook Medical
  • Bio Compression Systems
  • ThermoTek USA
  • Boston Scientific Corporation
  • Cardinal Health

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19024

The Global Venous Thromboembolism Prophylaxis Market is projected to expand from USD 6.89 Billion in 2025 to USD 9.57 Billion by 2031, progressing at a CAGR of 5.63%. This therapeutic sector encompasses the administration of anticoagulants alongside mechanical compression devices, all aimed at averting deep vein thrombosis and pulmonary embolism. The market's upward trajectory is primarily fueled by an aging global population and increasing hospitalization rates for major cardiac and orthopedic surgeries that mandate rigorous postsurgical preventative care. Additionally, the heightened acknowledgment of hospital-acquired clots as a preventable cause of mortality continues to uphold the demand for effective intervention protocols within healthcare facilities.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.89 Billion
Market Size 2031USD 9.57 Billion
CAGR 2026-20315.63%
Fastest Growing SegmentAmbulatory Care Centers
Largest MarketNorth America

Despite these growth drivers, the market faces significant hurdles due to the bleeding risks linked to potent pharmacological agents, which can discourage clinicians from strictly adhering to prophylactic guidelines. This caution restricts market penetration, even with the high prevalence of clotting disorders requiring attention. According to the International Society on Thrombosis and Haemostasis, in 2024, thrombosis-related conditions were responsible for one in four deaths globally, highlighting the critical need to balance therapeutic efficacy with patient safety when expanding the adoption of prophylactic measures.

Market Driver

The escalating volume of major surgical and orthopedic procedures serves as a primary market catalyst, requiring strict postsurgical prevention strategies to ensure patient safety. As healthcare systems clear pandemic-related backlogs, the frequency of high-risk interventions, such as total knee and hip arthroplasties, has risen, directly boosting the use of pharmacological prophylaxis and mechanical compression. This increase in surgical throughput necessitates that hospitals stock and administer prophylactic solutions to mitigate the deep vein thrombosis risks associated with operative trauma and prolonged immobilization. According to Stryker, January 2024, in the 'Fourth Quarter 2023 Operating Results', the company reported net sales growth of 11.5 percent to $5.8 billion, a performance largely attributed to the sustained momentum in surgical procedure volumes requiring concurrent preventative care.

Simultaneously, the rapid uptake of Novel Oral Anticoagulants (NOACs) is transforming the standard of care by providing superior safety profiles and easier administration compared to traditional vitamin K antagonists. Clinicians increasingly prefer these advanced therapies due to their predictable pharmacokinetics, which enhance patient compliance and reduce the need for continuous monitoring. According to Bristol Myers Squibb, February 2024, in the '2023 Annual Report', the leading oral anticoagulant Eliquis generated worldwide revenues of $12.2 billion, signaling a massive global shift toward these modern agents. This transition is further underscored by the persistent disease burden; according to the National Blood Clot Alliance, in 2024, blood clots affect approximately 900,000 people in the United States annually, driving the urgency for reliable prophylactic interventions throughout the continuum of care.

Market Challenge

A significant impediment facing the Global Venous Thromboembolism Prophylaxis Market is the risk of major bleeding associated with potent anticoagulant therapies. Clinicians frequently face the dilemma of balancing the benefits of clot prevention against the potential for life-threatening hemorrhagic complications, particularly among vulnerable groups like the elderly or patients recovering from extensive surgeries. This clinical caution often leads to the under-prescription of necessary pharmacological prophylaxis, dosage reductions, or premature therapy cessation. While clinically justified, such hesitation restricts the total volume of anticoagulants used and slows the adoption of prophylaxis protocols, thereby limiting overall market expansion.

This constraint is especially severe within high-risk patient populations that constitute a large segment of the addressable market. According to the American Society of Hematology, in 2023, medical inpatients and residents in long-term care facilities accounted for approximately 20% to 25% of all venous thromboembolism instances globally. Because these specific groups often present with comorbidities that increase their susceptibility to bleeding, the rigorous application of prophylaxis is frequently compromised by safety concerns, effectively curbing market penetration in a sector that otherwise generates substantial demand for preventative interventions.

Market Trends

The rise of portable and wearable mechanical prophylaxis devices is reshaping the recovery landscape by separating compression therapy from stationary hospital infrastructure. Unlike traditional pneumatic systems that keep patients tethered to bedside units, these battery-operated devices facilitate early mobilization, a critical factor in reducing venous stasis and enhancing patient adherence following discharge. This shift aligns with the increasing demand for home-based recovery solutions that preserve clinical efficacy without restricting patient mobility. The commercial viability of these technologies is highlighted by the financial results of key industry players; according to Enovis Corporation, February 2024, in the 'Fourth Quarter and Fiscal Year 2023 Results', the company's Prevention and Recovery segment posted full-year net sales growth of 5%, reflecting sustained demand for these mobile therapeutic solutions.

Simultaneously, the adoption of personalized prophylaxis protocols utilizing AI-driven risk assessment is superseding generic prevention strategies with precision medicine tools. Advanced algorithms now integrate with electronic health records to continuously monitor patient data, automatically identifying high-risk individuals who might be missed by manual scoring systems like Padua or Caprini. This automation ensures timely intervention for conditions such as pulmonary embolism and improves care coordination across fragmented hospital departments. The rapid uptake of these intelligent systems is evident in the growing reach of specialized AI providers; according to Viz.ai, January 2024, in the 'Viz.ai Adoption Surpasses 1,500 Hospitals Nationwide' press release, the user base for its AI-powered disease detection platform expanded by nearly 30% in 2023 to reach 45,000 healthcare providers.

Key Market Players

  • Arjo
  • Encompass Group
  • Argon Medical Devices
  • MEGO AFEK
  • Zenith Technical Innovations
  • Cook Medical
  • Bio Compression Systems
  • ThermoTek USA
  • Boston Scientific Corporation
  • Cardinal Health

Report Scope

In this report, the Global Venous Thromboembolism Prophylaxis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Venous Thromboembolism Prophylaxis Market, By Type

  • Lower Extremity
  • Upper Extremity

Venous Thromboembolism Prophylaxis Market, By End Use

  • Hospitals & Clinics
  • Ambulatory care Centers
  • Others

Venous Thromboembolism Prophylaxis Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Venous Thromboembolism Prophylaxis Market.

Available Customizations:

Global Venous Thromboembolism Prophylaxis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Venous Thromboembolism Prophylaxis Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Lower Extremity, Upper Extremity)
    • 5.2.2. By End Use (Hospitals & Clinics, Ambulatory care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Venous Thromboembolism Prophylaxis Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Venous Thromboembolism Prophylaxis Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By End Use
    • 6.3.2. Canada Venous Thromboembolism Prophylaxis Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By End Use
    • 6.3.3. Mexico Venous Thromboembolism Prophylaxis Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By End Use

7. Europe Venous Thromboembolism Prophylaxis Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By End Use
    • 7.3.2. France Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Venous Thromboembolism Prophylaxis Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By End Use

8. Asia Pacific Venous Thromboembolism Prophylaxis Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By End Use
    • 8.3.3. Japan Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By End Use
    • 8.3.4. South Korea Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Venous Thromboembolism Prophylaxis Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By End Use

9. Middle East & Africa Venous Thromboembolism Prophylaxis Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Venous Thromboembolism Prophylaxis Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By End Use
    • 9.3.2. UAE Venous Thromboembolism Prophylaxis Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By End Use
    • 9.3.3. South Africa Venous Thromboembolism Prophylaxis Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By End Use

10. South America Venous Thromboembolism Prophylaxis Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Venous Thromboembolism Prophylaxis Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By End Use
    • 10.3.2. Colombia Venous Thromboembolism Prophylaxis Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By End Use
    • 10.3.3. Argentina Venous Thromboembolism Prophylaxis Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Venous Thromboembolism Prophylaxis Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Arjo
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Encompass Group
  • 15.3. Argon Medical Devices
  • 15.4. MEGO AFEK
  • 15.5. Zenith Technical Innovations
  • 15.6. Cook Medical
  • 15.7. Bio Compression Systems
  • 15.8. ThermoTek USA
  • 15.9. Boston Scientific Corporation
  • 15.10. Cardinal Health

16. Strategic Recommendations

17. About Us & Disclaimer